Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise.
Phase of Trial: Phase IV
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck & Co
- 10 Jun 2017 Biomarkers information updated
- 30 Dec 2010 Trial location (Mexico) identified as reported by ClinicalTrials.gov.
- 19 Mar 2009 Status changed from active, no longer recruiting to completed.